P
Pharvaris N.V. (PHVS)
NMS – Real Time Price. Currency in USD
34.01
+0.71 (2.13%)
At close: Jun 26, 2026, 4:00 PM EDT
34.01
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
34.01
+0.71 (2.13%)
At close: Jun 26, 2026, 4:00 PM EDT
34.01
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
| Name | Position |
|---|---|
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer |
| Maryann Cimino | Director of Corporate Relations |
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, CEO & Executive Director |
| Mr. Wim Souverijns Ph.D. | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-26 | 6-K | annual_general_meeting_2.htm |
| 2026-06-11 | 6-K | 6-k_agm_pr_announcement_.htm |
| 2026-05-12 | 6-K | 6-k_q1_26.htm |
| 2026-05-11 | 6-K | d134419d6k.htm |
| 2026-04-02 | 6-K | pr_fin_results_2025.htm |
| 2026-04-02 | 20-F | phvs-20251231.htm |
| 2026-01-12 | 6-K | corporate_presentation_j.htm |
| 2025-12-03 | 6-K | d69798d6k.htm |
| 2025-11-12 | 6-K | 6-k_q3_25.htm |
| 2025-09-23 | POSASR | d57322dposasr.htm |